Robert Meehan

Medical Oncologist, Early Phase Clinical Trialist. All my tweets / comments are my own.

[Moderna @moderna_tx]

Moderna and @Merck today announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk #melanoma (stage III/IV) following complete resection.

The companies have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types.

Learn more: https://t.co/2qlw46qgdX

[Moderna @moderna_tx]

Welcome to the #mRNAge! One strand of mRNA could change how we stand up to multiple diseases – from the widespread to the extremely rare. It could even individualize how we approach cancer.

Watch our new mRNAge video that launched this week and learn what else #mRNA could do: https://t.co/8HRI1y8KG6.

#ThisChangesEverything

[AACR @AACR]

Harnessing the Immune System in the Clinic: Jeffrey S. Weber, MD, PhD; Reinhard Dummer, MD, PhD; Pierce Chow, MBBS, PhD; Eduardo Castañón, MD, PhD; and John V. Heymach, MD, PhD, presented Sunday at #AACR23. Read a recap in AACR Annual Meeting News:
https://t.co/RnQQVdNRL7

[Rick Buck @Rick__Buck]

More news coverage from ⁦@AACR⁩ Annual Meeting. Here is an NBC Nightly News story featuring a cancer vaccine study from our #AACR23 press program. https://t.co/CSjRLPmuJI

[Hussein Tawbi, MD, PhD @HTawbi_MDPhD]

Impressive results for mRNA personalized vaccine+ pembro in high risk resected melanoma (HR 0.56) clinically meaningful & statistically significant in the adjuvant setting in randomized Phase 2. Will need Phase 3 confirmation- planned to start soon congrats Jeff Weber & team

[AACR @AACR]

The first study in today’s press conference is presented by Jeffrey Weber, MD, PhD, from NYU Langone Perlmutter Cancer Center, and Ryan Sullivan, MD, from Mass General Cancer Center and Harvard Medical School. #AACR23 https://t.co/IM4hiQ5sTN

[Moderna @moderna_tx]

One therapy, for one patient. We, along with our partner @Merck, are pioneering a new frontier in the fight against #cancer by designing an mRNA-based investigational individualized #neoantigen therapy - that targets each patient’s unique cancer cells.

Learn more ⬇

[The Wall Street Journal @WSJ]

Moderna’s mRNA cancer vaccine helped prevent relapse for melanoma patients, results from a mid-stage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system https://t.co/Bxrck6jOMl

[Moderna @moderna_tx]

Dr. Jeffrey S. Weber’s presentation starts shortly - join him at the Chapin Theatre!
https://t.co/RdHfV7IyYq
#AACR23

[Moderna @moderna_tx]

Stéphane Bancel, our Chief Executive Officer, discusses the potential promise of mRNA-4157/V940, our investigational #mRNA individualized neoantigen #therapy, and Phase 2b study data that will be presented at #AACR23. Read the full blog here: https://t.co/udXqUP68s7

[Moderna @moderna_tx]

Today, Moderna and Merck announced the first presentation of detailed results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen #therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with resected high-risk #melanoma (stage III/IV).

These findings will be presented during the 2023 @AACR Annual Meeting plenary session (Abstract #CT001).

Data from a subgroup analysis of KEYNOTE-942/mRNA-4157-P201 (Abstract #CT224) evaluating mRNA-4157 (V940) in combination with KEYTRUDA among patients based on tumor mutational burden (TMB) status will also be presented.

Learn more: https://t.co/7WMzNKUlsP

#AACR23

[Moderna @moderna_tx]

Heading to #AACR23? Stop by our booth at the @AACR Annual Cancer and Biomedical Career Fair. Our team is excited to chat about opportunities to work in #oncology research at Moderna!

Learn more: https://t.co/JMKexufWPF

[Moderna @moderna_tx]

We announced today that mRNA-4157/V940, an investigational personalized #mRNA #cancer vaccine, in combination with KEYTRUDA, @Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy Designation by the U.S. FDA for the adjuvant treatment of patients with high-risk #melanoma following complete resection.

The FDA granted Breakthrough Therapy Designation based on positive data from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial.

The FDA’s Breakthrough Therapy Designation is granted to expedite the development and review of drugs that are intended to treat a serious condition, and when preliminary clinical evidence indicates that the product may demonstrate substantial improvement over available therapies on at least one clinically significant endpoint.

Read more: https://t.co/5jwP0Wj2XE

[Geraldine O'Sullivan Coyne @geosullivanc]

Editorial: Special issue on rare cancers - ScienceDirect ⁦@NCI_CCR_PedOnc⁩ #CurrProbCancer ⁦@NCItreatment⁩ ⁦@OncologyAdvance⁩ #RareCancer https://t.co/ugHDamCodB

[Elad Sharon @EladSharonMD]

If you have cancer, either are on PD1/PDL1 or are a heme patient, AND have NOT been vaccinated -> Come to #BETHESDA, Maryland! I will get you vaccinated, learn more about how the immune system responds to #covid19 and new antigens in general! https://t.co/RzxaYvUJhu @NIH @theNCI

[@gulleyj1 @gulleyj1]

Proud that @nciccr_gmb, @NCIResearchCtr is the home for this study led by @EladSharonMD studying the #immune responses of #COVID19 #Vaccine in #Cancer pts with ⬆️immune activation (on immune checkpoint inhibitors) or ⬇️immune system (heme malignancies) https://t.co/TdzKkVGpO5

[Geraldine O'Sullivan Coyne @geosullivanc]

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors #NCIDTC @NCItreatment @NCIResearchCtr together with colleagues @DanaFarber #HSP90 https://t.co/TX10AsZUPi Cancer Chemotherapy and Pharmacology

[Geraldine O'Sullivan Coyne @geosullivanc]

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas #NCIDTC @NCItreatment @NCIResearchCtr @Oncotarget https://t.co/m7e8I3KCh1

[Moderna @moderna_tx]

We just announced the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, our COVID-19 vaccine candidate and that today, we plan to request an Emergency Use Authorization from the U.S. FDA & conditional approval from the EMA. Read more: https://t.co/90FbcVHdWN

[Gal Cafri @GalCafri]

Our paper describing the vaccination of gastrointestinal cancer patients with mRNA encoding for defined neoantigens is out.
A 3-year collaboration between the @NCI_CCR_SB and @moderna_tx
https://t.co/gaL1D3w6QR